Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuromed Pharmaceuticals Ltd.

Division of Epirus Biopharmaceuticals Inc.
www.neuromed.com

Latest From Neuromed Pharmaceuticals Ltd.

STOCKWATCH: Name, Platform; Time of death, December 2013

They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.

Cardiovascular Cancer

Zalicus shifts focus to pain after lead project Synavive fails in arthritis

It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.

Immune Disorders Orthopedics

CombinatoRx posts profit in Q4

CombinatoRx has reported a fourth quarter profit of $25.2 million on lower R&D spending and gains from its acquisition of Neuromed Pharmaceuticals. The US firm's shares closed up by 8% to $1.36 yesterday after swinging from a fourth-quarter loss of $15.2 million the year before.

Companies

CombinatoRx and Neuromed complete merger

CombinatoRx and privately held Neuromed Pharmaceuticals announced yesterday that they have closed their $28.8 million all-stock merger.

Neurology Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neuromed Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Epirus Biopharmaceuticals Inc.
  • Senior Management
  • Bruce S Colwill, CFO
    Jeffrey Acara, VP, Bus. Dev.
    Terrance P Snutch, PhD, CSO
    Mario Orlando, VP, Mktg.
  • Contact Info
  • Neuromed Pharmaceuticals Ltd.
    Phone: (604) 909-2530
    301-2389 Health Sciences Mall, UBC
    Don Rix Bldg.
    Vancouver, V6T 1Z3
    Canada
UsernamePublicRestriction

Register